What the Pipeline Holds

The previous installment addressed the systems around your medicine cabinet: what drugs cost, who pays, and how pricing reform and care models are beginning to shift. This one looks at the drugs themselves. What is genuinely new? What is close to reaching your pharmacy shelf? And for which conditions does the pipeline remain stubbornly empty?

The honest answer is that some areas of drug development have moved further in the past five years than in the prior twenty. Others have barely moved at all. What follows is a condition-by-condition survey, grounded in where things actually stand rather than where press releases suggest they might.

Pain: The First New Class in Two Decades

For the first time in more than twenty years, a genuinely new class of pain medication has reached the pharmacy shelf. Suzetrigine, sold under the brand name Journavx, received FDA approval in January 2025 for moderate to severe acute pain. It works by blocking a specific sodium channel (NaV1.8) in peripheral nerves, intercepting pain signals before they reach the brain. Because it does not act on the central nervous system at all, it carries no addiction risk, no sedation, and no respiratory depression.

As installment 3C described, the opioid crisis hit older adults from both directions: first through overprescription, then through an overcorrection that left legitimate pain undertreated. Suzetrigine offers a third path. In trials, it outperformed placebo for post-surgical pain. It did not outperform the standard opioid combination of hydrocodone plus acetaminophen, but the advantage is not potency. It is safety.

The cost is the immediate problem. Suzetrigine lists at $15.50 per pill, roughly $31 per day. A week’s course runs about $420. Generic hydrocodone costs a fraction of that. For a Medicare beneficiary whose plan does not yet list it, suzetrigine might as well not exist. Vertex Pharmaceuticals is running Phase 3 trials for diabetic peripheral neuropathy, a condition affecting millions of older adults. If those trials succeed, the drug’s relevance grows considerably. If.

Cholesterol: The Twice-a-Year Injection

If installment 3G’s core argument was that too many pills create compounding risks, inclisiran (Leqvio) represents a different kind of answer. It is a small interfering RNA that silences the liver’s production of PCSK9, a protein that prevents the body from clearing LDL cholesterol efficiently. Instead of a daily statin, inclisiran is administered as a subcutaneous injection at a doctor’s office: an initial dose, another at three months, then twice a year thereafter.

The clinical data on LDL reduction is clear: roughly 50 percent reduction sustained over six years of follow-up data, with a safety profile comparable to placebo in pooled analyses across seven trials. In July 2025, the FDA expanded its label to allow use as monotherapy alongside diet and exercise, removing the prior requirement that it be combined with a statin. For statin-intolerant patients, a population that skews older, that change matters.

What inclisiran does not yet have is cardiovascular outcomes data. The ORION-4 trial, with 15,000 patients aged 55 and older, should report results by mid-2026 and will show whether the LDL reduction translates into fewer heart attacks and strokes. That gap is real. Doctors prescribe it based on the well-established relationship between LDL reduction and cardiovascular risk, but confirmation from a dedicated outcomes trial is still pending.

The cost is $6,500 per year ($3,250 per injection). Because it is administered in a doctor’s office, it falls under the medical benefit pathway rather than pharmacy benefits. Novartis has said this should mean 70 percent of eligible Medicare fee-for-service patients face zero copay, though Medicare Advantage and commercial coverage is still catching up. The adherence argument is powerful: a person who never remembers to take a statin gets the same LDL reduction as someone who takes it perfectly, because the doctor administers the dose during a regular visit. For older adults managing a dozen other medications, that matters more than the molecular mechanism.

Heart and Kidney: Drugs That Cross Organ Lines

The SGLT2 inhibitors may be the most consequential drug class expansion of this decade for older adults. Originally approved for type 2 diabetes, drugs like empagliflozin (Jardiance) and dapagliflozin (Farxiga) now carry FDA approvals for heart failure and chronic kidney disease, regardless of whether the patient has diabetes at all.

The trial data is substantial. In heart failure, SGLT2 inhibitors reduced cardiovascular death and hospitalization by roughly 25 percent across both reduced and preserved ejection fraction, the latter being a condition that had almost no effective pharmacological treatment before 2022. In chronic kidney disease, they slowed the progression toward dialysis significantly enough that the 2024 KDIGO guidelines now list them as foundational therapy for CKD patients with an eGFR of 20 or above.

Finerenone (Kerendia), approved in 2021, adds a second layer of protection specifically for kidneys damaged by diabetes. It works through a different pathway, blocking the overactivation of mineralocorticoid receptors that drives inflammation and scarring in kidney tissue. The FIDELITY pooled analysis of over 13,000 patients showed finerenone reduced kidney disease progression by 23 percent and cardiovascular events by 14 percent compared to placebo when added to standard care. In November 2025, finerenone also became the first drug in 30 years to show positive Phase 3 results for kidney disease in type 1 diabetes.

The practical point: finerenone is not a replacement for SGLT2 inhibitors. It is additive. Current guidelines recommend using both together alongside an ACE inhibitor or ARB for diabetic kidney disease, creating a three-drug foundation that addresses different aspects of the damage. For readers who followed installment 3B on diabetes, this triple therapy represents a genuine shift from treating blood sugar alone to protecting the organs that diabetes quietly destroys. Finerenone costs roughly $600 per month, and its main risk is elevated potassium, which requires monitoring.

Both empagliflozin and dapagliflozin were selected for the first round of Medicare drug price negotiations under the Inflation Reduction Act, with negotiated prices taking effect in 2026. Finerenone has not yet been included. Until those reductions arrive, access depends on insurance formularies, and coverage remains uneven.

Diabetes and Beyond: The GLP-1 Expansion

The GLP-1 receptor agonists continue to expand their reach beyond blood sugar. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have shown benefits for cardiovascular disease, chronic kidney disease, and sleep apnea. The FLOW trial confirmed semaglutide’s kidney-protective effects independently of its metabolic benefits. Early research suggests possible cognitive benefits, though those findings remain preliminary and years from clinical relevance.

What matters for the medicine cabinet is consolidation. A single GLP-1 injection may eventually replace two or three separate prescriptions for conditions that currently require separate management: blood sugar, cardiovascular risk, and weight. For a person taking one medication for each of those, a GLP-1 could do the work of all three. The next generation is already in trials: retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, showed weight loss of up to 24 percent in Phase 2 data, though Phase 3 results are still years away.

That consolidation, if it bears out, would directly address the polypharmacy problem 3G described. Fewer pills, fewer interactions, fewer chances for the prescribing cascade to start. Semaglutide is among the 15 drugs selected for the second round of IRA price negotiations, with negotiated prices expected for 2027. Current out-of-pocket costs can reach $1,000 or more per month, and prior authorization requirements create access barriers that disproportionately affect older adults.

Blood Clots: Anticoagulants Without the Bleeding

Millions of older adults take blood thinners for atrial fibrillation, a condition that affects roughly 10 percent of people over 80. Current anticoagulants (warfarin, apixaban, rivaroxaban) are effective at preventing strokes but carry a persistent trade-off: bleeding. The risk of major hemorrhage rises with age, which is precisely when the need for stroke prevention is highest. Some patients are taken off anticoagulants entirely because the bleeding risk is judged too dangerous, leaving them unprotected against stroke.

Factor XI inhibitors aim to break that trade-off. They target a clotting factor involved in forming dangerous clots inside blood vessels but less involved in the normal wound-healing response that stops cuts and injuries from bleeding. The result, at least in early trials, is clot prevention with far less bleeding.

The most advanced is abelacimab, a monthly subcutaneous injection. In the AZALEA-TIMI 71 trial, published in the New England Journal of Medicine in January 2025, abelacimab reduced major or clinically relevant bleeding by roughly 60 to 70 percent compared to rivaroxaban in patients with atrial fibrillation. The trial was stopped early because the safety advantage was larger than expected. A February 2026 analysis found the benefit was even greater in patients 75 and older, with bleeding risk remaining flat across age groups for abelacimab while rising steeply with rivaroxaban.

There is a significant caveat. The AZALEA trial was designed to measure safety (bleeding), not efficacy (stroke prevention). There was a small, non-significant increase in strokes with abelacimab, and the study was not large enough to determine whether the drug prevents strokes as effectively as current anticoagulants. The Phase 3 LILAC trial is now testing abelacimab in patients deemed unsuitable for current anticoagulants, a population that currently has no good options. Oral Factor XI inhibitors (milvexian from Bristol Myers Squibb) are also in Phase 3 trials, with results expected in 2026 and 2027.

If the Phase 3 data confirms what the Phase 2 trials suggest, Factor XI inhibitors could transform anticoagulation for the oldest and most vulnerable patients. That is a meaningful “if.” But the OCEANIC-AF trial of a different Factor XI inhibitor, asundexian, was stopped early for lack of efficacy, a reminder that this class is not guaranteed to succeed.

Bones: A Drug That Builds Instead of Preserving

Most osteoporosis medications work by slowing bone loss. Romosozumab (Evenity), approved by the FDA in 2019, does something different: it actually builds new bone while simultaneously reducing breakdown. It is the first and only drug in its class, a sclerostin inhibitor that targets a protein regulating bone metabolism.

The clinical data is strong. In postmenopausal women with osteoporosis, romosozumab reduced new vertebral fractures by 73 percent compared to placebo at twelve months. When followed by the standard anti-resorptive drug denosumab, that benefit persisted through three years. In women with prior fractures (the highest-risk group), romosozumab followed by alendronate cut vertebral fracture risk by 50 percent compared to alendronate alone.

Installment 3F described the treatment gap: fewer than 25 percent of fracture patients receive appropriate osteoporosis medication. Romosozumab is not the answer for most of them; it is approved only for postmenopausal women at high risk of fracture, and treatment is limited to twelve monthly injections. It also carries an FDA boxed warning for cardiovascular risk: the ARCH trial showed a higher rate of serious cardiovascular events compared to alendronate, and it is contraindicated in patients with recent heart attack or stroke.

For the right patient, someone with severe osteoporosis, prior fractures, and no significant cardiovascular history, romosozumab represents something genuinely new. For most people with osteoporosis, the more pressing issue remains what 3F described: getting any treatment at all.

Arthritis: Oral Convenience, Serious Trade-offs

JAK inhibitors (tofacitinib, baricitinib, upadacitinib) offered something appealing for rheumatoid arthritis: oral pills instead of injections, with efficacy comparable to biologic therapies. Then came the ORAL Surveillance trial, and the landscape shifted.

That post-marketing safety study found tofacitinib carried a 33 percent higher risk of major cardiovascular events and a 48 percent increased risk of malignancy compared to TNF inhibitors, specifically in patients 50 and older with at least one cardiovascular risk factor. The FDA responded with boxed warnings across the entire class and restricted JAK inhibitors to patients who had failed TNF blocker therapy first.

For older adults with arthritis, this creates a complicated calculus. JAK inhibitors work. They are convenient. They can address both inflammatory and non-inflammatory pain. But the safety profile is worse in precisely the population most likely to have cardiovascular risk factors. Real-world data from the STAR-RA trial found the malignancy risk with tofacitinib was not elevated in a broader population, suggesting the risk may be concentrated in those with pre-existing cardiovascular vulnerability. Newer, more selective JAK inhibitors like upadacitinib may carry lower risk, but the class-wide warning remains.

These drugs are available now. They are not in the pipeline. But they illustrate a pattern that recurs throughout this survey: a drug that works well comes with trade-offs that hit older adults hardest.

Migraine: Better Prevention, Familiar Barriers

The CGRP inhibitors (erenumab, fremanezumab, galcanezumab, eptinezumab) represent a genuine advance for migraine prevention, the first drugs designed specifically for migraine rather than repurposed from other conditions. They work by blocking calcitonin gene-related peptide, a protein released during migraine attacks. Oral versions called gepants (rimegepant, atogepant) offer the same mechanism without injections.

These drugs are relevant to this series because migraine does not disappear with age, and older adults have fewer safe options for treatment. Triptans carry cardiovascular risks. NSAIDs carry gastrointestinal and renal risks. CGRP inhibitors sidestep both of those concerns, with side effect profiles limited mostly to injection site reactions and constipation.

The barrier is cost. CGRP monoclonal antibodies run $600 to $700 per month without insurance. Medicare coverage varies by plan, and prior authorization often requires documented failure of multiple cheaper alternatives first. For older adults whose migraines were never adequately treated because available options were too risky, CGRP inhibitors are a genuine advance locked behind a familiar gate.

Lungs: The First Biologic for COPD

Chronic obstructive pulmonary disease affects millions of older adults, most of them current or former smokers. Until September 2024, every COPD treatment worked the same broad way: bronchodilators to open airways, steroids to reduce inflammation, or combinations of both. None targeted the specific inflammatory pathways driving the disease in individual patients.

Dupilumab (Dupixent), already approved for asthma, eczema, and several other inflammatory conditions, became the first biologic for COPD when the FDA approved it as an add-on treatment for adults with inadequately controlled disease and an eosinophilic phenotype, meaning elevated levels of a specific white blood cell. In Phase 3 trials (BOREAS and NOTUS), dupilumab reduced moderate to severe COPD flare-ups by 30 to 34 percent and improved lung function compared to placebo over one year.

The limitation is specificity. Dupilumab works only for the eosinophilic subtype of COPD. The FDA estimates roughly 300,000 adults in the United States qualify. That is a fraction of the total COPD population. But for those 300,000, many of whom have been cycling through the same inhaler combinations for years without adequate control, it offers a genuinely different approach.

The cost is steep: roughly $3,100 per month for two prefilled pens. It falls under Medicare Part D, where 99 percent of plans cover it but most require prior authorization and often step therapy (proving cheaper options have failed first). About 79 percent of Medicare Part D patients pay $100 or less per month after coverage kicks in. A second COPD biologic, mepolizumab (Nucala), was approved in May 2025, expanding the options slightly but following the same pattern of high cost and biomarker-dependent eligibility.

Cognitive Decline: A Door Opened, Barely

Lecanemab (Leqembi) and donanemab (Kisunla) are the first Alzheimer’s treatments that address the underlying biology of the disease rather than just managing symptoms. Both clear beta-amyloid plaques from the brain. Both have received full FDA approval. Series 2 of Blue Gray Matters will cover these drugs in depth, so this installment offers only the essential summary.

Lecanemab slowed cognitive decline by roughly 27 percent over 18 months compared to placebo, which translates to about five additional months before reaching the next stage of decline. Donanemab showed similar benefit, with the added possibility of stopping treatment once amyloid clearance is confirmed on brain scans. Both carry the risk of ARIA (amyloid-related imaging abnormalities), brain swelling or micro-bleeds that are more common in people carrying two copies of the ApoE4 gene.

Medicare covers both drugs under a real-world evidence registry, but the practical barriers are steep. Lecanemab lists at $26,500 per year. The total cost of treatment, including genetic testing, PET scans, and safety monitoring, can reach $82,500 annually. The 20 percent coinsurance under Part B means roughly $6,600 out of pocket for patients without supplemental coverage. Access is further limited by the shortage of specialists capable of managing these drugs, particularly in rural areas.

These are real treatments with real, if modest, effects. They are also expensive, logistically demanding, and available only to people in the earliest stages of the disease. The pipeline beyond amyloid, targeting tau, neuroinflammation, and synaptic resilience, has over 160 active clinical trials. Whether any of them will produce something more effective, more accessible, or both remains an open question that Series 2 will follow closely.

Muscle Loss: The Empty Shelf

And then there is sarcopenia, the progressive loss of muscle mass and strength that installment 3F described alongside osteoporosis. There is no FDA-approved drug for sarcopenia. None.

This is not for lack of trying. At least nine companies have developed myostatin inhibitors, drugs targeting a protein that normally limits muscle growth. The results have been consistently frustrating. Bimagrumab, the furthest along, increased lean body mass by 6 to 8 percent in older adults with sarcopenia, but improvements in actual muscle strength and physical function were minimal. You can grow bigger muscles pharmacologically; making them work better has proved far harder.

The most promising recent development is indirect. Myostatin inhibitors like bimagrumab and apitegromab are being tested in combination with GLP-1 drugs to preserve muscle mass during weight loss, a significant concern given that up to 40 percent of weight lost on semaglutide comes from lean tissue. Apitegromab combined with tirzepatide preserved nearly 55 percent more lean mass than tirzepatide alone in one trial. If these combinations succeed, sarcopenia treatment may arrive through the side door of obesity medicine rather than through a direct assault on age-related muscle loss.

Meanwhile, Epirium Bio reported positive Phase 1 results for MF-300, a novel oral drug targeting a different pathway entirely (the enzyme 15-PGDH). Phase 1 means safety testing in healthy adults. Clinical efficacy data in people with sarcopenia is years away. For now, the only evidence-based intervention for sarcopenia remains resistance exercise and adequate protein intake. No pill replaces the work.

What This Survey Shows

The pattern across these twelve areas is consistent. Where drugs exist, they tend to be expensive, access-dependent, and complicated by trade-offs that are amplified in older bodies. Where drugs are genuinely new, the first question is not “does it work?” but “can I get it?” Where the need is greatest (sarcopenia, advanced dementia, chronic pain beyond the acute phase), the pipeline is thinnest.

Some of these drugs suggest a different kind of future. Inclisiran eliminates daily pills for cholesterol. SGLT2 inhibitors and GLP-1 agonists treat multiple organs with one prescription, reversing the fragmentation that polypharmacy creates. Factor XI inhibitors may finally separate clot prevention from bleeding risk. Dupilumab opens a door for COPD patients who have exhausted conventional options. These are real advances. They deserve honest excitement rather than either hype or dismissal.

But none of them matters if the pricing, coverage, and care systems described in 3H do not evolve fast enough to deliver them. The installments that preceded this one described the conditions. The previous one described the cost structures. This one has tried to show what is actually in the pipeline and what is still missing. What connects all three is a simple reality: the medicine cabinet five years from now will be shaped not only by which molecules succeed in trials, but by whether the infrastructure exists to get them into the hands of the people who need them.

The next installment turns from what you take to what lives inside you. The gut-brain axis, the microbiome, and what the newest research says about the connection between your digestive system and your cognitive health.

Blue Gray Matters explores the physiological, psychological, philosophical, sociological, and economic dimensions of aging. Series 3 examines what happens to the body after 60.